JP Morgan Chase
SUPN icon

JP Morgan Chase’s Supernus Pharmaceuticals SUPN Stock Holding History

JP Morgan Chase’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-150,000
Closed -$8.98M – 5818
2018
Q2 		$8.98M Buy
+150,000
New +$7.77M ﹤0.01% 2233

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

JP Morgan Chase's SUPN Position: Q2 2026 in Review

JP Morgan Chase increased its Supernus Pharmaceuticals (SUPN) stake by 8.6% in Q2 2026, buying an estimated $1.04M and bringing the position to 272,329 shares worth $12.9M. The position accounts for ﹤0.01% of the portfolio, ranked #2593.

JP Morgan Chase first reported a position in SUPN in Q4 2015 and has held it in 43 quarters since. The position peaked at $21.1M in Q1 2018. 335 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

  • JP Morgan Chase held 272,329 shares of Supernus Pharmaceuticals worth $12.9M as of Q2 2026.
  • JP Morgan Chase bought 21,594 Supernus Pharmaceuticals shares in Q2 2026, an estimated $1.04M.
  • Supernus Pharmaceuticals made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #2593 holding.
  • JP Morgan Chase first reported a position in Supernus Pharmaceuticals in Q4 2015 and has held it in 43 quarters since.
  • JP Morgan Chase's Supernus Pharmaceuticals position peaked at $21.1M in Q1 2018.
  • 335 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.